AbbVie Inc., submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the U.S. Food and Drug Administration (FDA) to treat major depressive disorder (MDD) in patients receiving existing antidepressants.
Alkermes, announced the receiving of Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD).
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?